Log in

NASDAQ:AVEOAVEO Pharmaceuticals Stock Price, Forecast & News

+0.04 (+0.88 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $4.60
50-Day Range
MA: $4.71
52-Week Range
Now: $4.60
Volume199,643 shs
Average Volume370,986 shs
Market Capitalization$73.97 million
P/E Ratio7.54
Dividend YieldN/A
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody for the treatment of squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Read More
AVEO Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.07 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AVEO



Sales & Book Value

Annual Sales$28.80 million
Cash Flow$0.59 per share
Book Value$0.92 per share


Net Income$9.39 million


Market Cap$73.97 million
Next Earnings Date8/13/2020 (Estimated)
+0.04 (+0.88 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

How has AVEO Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

AVEO Pharmaceuticals' stock was trading at $3.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AVEO stock has increased by 31.8% and is now trading at $4.60.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of AVEO Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AVEO Pharmaceuticals

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for AVEO Pharmaceuticals

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its quarterly earnings data on Thursday, April, 30th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.02. The biopharmaceutical company had revenue of $0.78 million for the quarter, compared to analysts' expectations of $2.25 million. AVEO Pharmaceuticals had a net margin of 1.62% and a return on equity of 4.28%.
View AVEO Pharmaceuticals' earnings history

When did AVEO Pharmaceuticals' stock split? How did AVEO Pharmaceuticals' stock split work?

AVEO Pharmaceuticals's stock reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for AVEO?

4 Wall Street analysts have issued 12-month target prices for AVEO Pharmaceuticals' shares. Their forecasts range from $12.00 to $26.00. On average, they anticipate AVEO Pharmaceuticals' share price to reach $20.50 in the next twelve months. This suggests a possible upside of 345.7% from the stock's current price.
View analysts' price targets for AVEO Pharmaceuticals

What are Wall Street analysts saying about AVEO Pharmaceuticals stock?

Here are some recent quotes from research analysts about AVEO Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AVEO got a huge boost from the approval for Fotivda in Europe for the first-line treatment of advanced renal cell carcinoma. However, it faced a major setback when it had to delay the new drug application filling for Fotivda in the United States. In September 2019, AVEO announced updated data from the second prespecified analysis of overall survival from the phase III study on Fotivda. The results included an OS hazard ratio of less than one, favoring Fotivda. Failure to receive regulatory approvals or termination of any deal would significantly hurt the stock in future. AVEO receives royalties from Fotivda sales in certain European countries. This is another revenue driver. Shares have underperformed the industry in the past year. Estimates looks stable ahead of Q4 earnings. AVEO has a mixed record earnings surprises in recent quarters." (2/21/2020)
  • 2. HC Wainwright analysts commented, "We raise our rating on AVEO to and increase our 12-month price target to $1.75 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030, assuming a 12.0% discount rate and a 0% terminal growth rate. We derive an rNPV of $393M for the products and add in pro forma net cash and cash equivalents of $65.2M to arrive at a 12-month price target of $1.75 per share. (1) clinical; (2) commercial; (3) financial; (4) partnership; and (5) intellectual property." (9/11/2019)

Has AVEO Pharmaceuticals been receiving favorable news coverage?

Media stories about AVEO stock have been trending very positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about AVEO Pharmaceuticals

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a drop in short interest in the month of July. As of July 31st, there was short interest totaling 1,390,000 shares, a drop of 24.5% from the July 15th total of 1,840,000 shares. Based on an average daily trading volume, of 941,300 shares, the short-interest ratio is currently 1.5 days. Currently, 6.8% of the shares of the stock are sold short.
View AVEO Pharmaceuticals' Current Options Chain

Who are some of AVEO Pharmaceuticals' key competitors?

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Advanced Micro Devices (AMD), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Novavax (NVAX), Amarin (AMRN), Opko Health (OPK), Inovio Pharmaceuticals (INO), Canopy Growth (CGC) and Alibaba Group (BABA).

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the following people:
  • Mr. Michael P. Bailey, CEO, Pres & Director (Age 54)
  • Ms. Karuna Rubin, Sr. VP & Gen. Counsel (Age 42)
  • Dr. Michael N. Needle, Chief Medical Officer (Age 59)
  • Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 60)
  • Dr. Emile Farhan Ph.D., VP of Technical Operations

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (24.58%), WINTON GROUP Ltd (0.29%), Strs Ohio (0.25%), New York State Common Retirement Fund (0.12%), Wedbush Securities Inc. (0.07%) and UBS Group AG (0.03%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris and Peter W Sonsini.
View institutional ownership trends for AVEO Pharmaceuticals

Which institutional investors are selling AVEO Pharmaceuticals stock?

AVEO stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd.
View insider buying and selling activity for AVEO Pharmaceuticals

Which institutional investors are buying AVEO Pharmaceuticals stock?

AVEO stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Strs Ohio, New York State Common Retirement Fund, Wedbush Securities Inc., and UBS Group AG. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, and Peter W Sonsini.
View insider buying and selling activity for AVEO Pharmaceuticals

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $4.60.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $73.97 million and generates $28.80 million in revenue each year. The biopharmaceutical company earns $9.39 million in net income (profit) each year or $0.61 on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is www.aveooncology.com.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.